Description: Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Home Page: www.epigenomics.com
Geneststrasse 5
Berlin,
10829
Germany
Phone:
49 30 243 450
Officers
| Name | Title |
|---|---|
| Mr. Gregory K. Hamilton | CEO & Member of the Exec. Board |
| Dr. Andrew A. Lukowiak Ph.D. | Pres & Chief Scientific Officer |
| Mr. Jens Ravens | CFO & Member of Exec. Board |
| Frederic Hilke | Investor Relations Officer |
| Dr. Noel Thomas Doheny | Chief Exec. Officer of Epigenomics Inc. |
Exchange: OTCQX
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.393 |
| Price-to-Sales TTM: | 10.6423 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 36 |